Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

Abstract: The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.

Abstract: The present invention relates to composition comprising cyclodextrins and a NO-releasing drug of formula, A-X-L-NOn, wherein A is the radical deriving from a drug; X is a divalent radical connecting A with the NO-releasing group L-NOn; L is selected from the group consisting of: O and S; n is 1 or 2.

Abstract: Sulphaminoheparosansulphates obtainable from the Escherichia coli K5 polysaccharide by deacetilation and the subsequent sulfation with the sulphuric anhydride/trimethylamine adduct carried out at 0° C., for times ranging from 0.25 to 2 hours and using a reactant/polysaccharide ratio (SO3 equivalents/available OH groups equivalents) equal to 5 have been found having high anti-metastatic activity and low anticoagulant activity.

Abstract: The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

Abstract: Glycosaminoglycans having high antithrombotic activity in vitro, obtained by various kinds of glycosaminoglycans supersulfated by the preparation of the salt of an organic base of the starting supersaturated glycosaminoglycan, by partial solvolytic desulfation of said salt and N-resulfation of said partially desulfated product.

Abstract: The invention relates to a cationic polysaccharide, preferably in fibrous form, having superabsorbent characteristics. The polysaccharides are substituted by quaternary ammonium groups, have a ds of at least 0.5, preferably 0.5 to 2.5 and are cross-linked to a sufficient extent that it remains insufficient in water. The polysaccharide is preferably cellulose. An increased number of functional groups in the product improves superabsorbent properties, whereas use of a cross-linking agent makes it possible to control the gel strength of the product and makes it easier to tailor the characteristics of the product to those which are required.

Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Abstract: Heparins, heparin fractions or fragments, optionally salified with pharmaceutically acceptable cations, having molecular weight ranging from 1.000 to 30.000 D, characterized by an EDTA content lower than 0.1%, by the absence, in the .sup.1 H--NMR spectra, of the signals due to EDTA between 2.50 and 4.00 p.p.m. and substantially free from bleeding effect and optionally free from signals, in the .sup.13 C--NMR spectrum, from 80 to 86 ppm.

Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GM1) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GM1 with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Abstract: Inclusion complexes of dipyridamole with beta cyclodextrins in the molar ratio of dipyridamole to cyclodextrin ranging from 1:1 to 1:12 provides higher and more consistent blood concentrations than can be achieved by the dipyridamole alone.

Abstract: Novel derivatives are disclosed as obtained from chondroitin sulfate, dermatan sulfate and hyaluronic acid, having a molar ratio between sulfate groups and carboxylic groups like that of heparin and furthermore characterized by possessing, as the heparin, the sulfoamino group at the carbon atom at the 6 position of hexosamine.The novel compounds show a very remarkable clearing activity in comparison with the starting mucopolysaccharides, this activity being similar and for some derivatives comparable with that of heparin.Moreover, differently from what normally happens upon sulfating the sulfomucopolysaccharides, the anticoagulating activity of the novel compounds is negligible or anyhow very reduced.The compounds of the present invention find use in the therapy of arteriosclerosis.

Abstract: Process for the depolymerization and sulfation of polysaccharides by reaction of said polysaccharides with a sulfuric acid/chlorosulfonic acid mixture.

Abstract: Novel depolymerized and supersulfated heparin having a molecular weight comprised between 2000 and 9000 and a sulfation degree of at least 2.5, in which all of the primary hydroxy groups are sulfated; a process for its preparation by reacting a heparin of natural origin, or a fraction thereof with a sulfuric acid/chlorosulfonic acid mixture; and pharmaceutical compositions containing it as active ingredient, having potential antithrombotic, hypolipemic and fibrinolytic activity and useful in the prevention of thrombosis and for the treatment of atherosclerosis.

Abstract: A process for the controlled degradation of liquid glucose syrups in concentrated solution and in homogeneous phase wherein the reducing groups of glucose, maltose and maltodextrin are converted into the salts of the corresponding aldonic acids and/or into the salts of lower carboxylic acids (C.sub.1 -C.sub.4) without substantially changing the polysaccharide components (degree of polymerization>3) of maltodextrin, or with only partial depolymerization of the polysaccharide components, by using simple oxidants such as hypohalogenites or ferricyanides, or aqueous alkaline solutions. The conversion of the reducing sugars is equal to or greater than 95%, and a very high reproductibility of the desired results is obtained. The invention also concerns the product obtained by the process and its use as an additive to cement mortars and concretes.

Abstract: A novel polyaminic resin obtained by crosslinking a polyalkyleneamine (in particular polyethyleneamine) with diisocyanates in solution, is useful as a selective separation or extraction agent of a component having a "complementary" chemical structure (particularly heparin), by means of mere contact or "ionic exchange" with aqueous solutions containing it. Heparin is thus even quantitatively extracted from solutions containing it alone or in mixture with other glucosaminoglycanes. The polyamine can then release the "adsorbed" heparin and be recovered by a treatment with saline solutions. The novel resin is used in pharmaco-biological fields.

Abstract: A novel polyaminic resin obtained by crosslinking a polyalkyleneamine (in particular polyethyleneamine) with diisocyanates in solution, is useful as a selective separation or extraction agent of a component having a "complementary" chemical structure (particularly heparin), by means of mere contact or "ionic exchange" with aqueous solutions containing it. Heparin is thus even quantitatively extracted from solutions containing it alone or in mixture with other glucosaminoglycanes. The polyamine can then release the "adsorbed" heparin and be recovered by a treatment with saline solutions. The novel resin is used in pharmaco-biological fields.